Bank of Nova Scotia
BIO icon

Bank of Nova Scotia’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bank of Nova Scotia’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7M Buy
+39,708
New +$11.3M 0.02% 453
2024
Q4 		– Sell
-861
Closed -$288K – 1056
2024
Q3 		$288K Sell
861
-1,239
-59% -$394K ﹤0.01% 919
2024
Q2 		$574K Sell
2,100
-562
-21% -$163K ﹤0.01% 834
2024
Q1 		$921K Buy
2,662
+28
+1% +$9.21K ﹤0.01% 786
2023
Q4 		$850K Buy
2,634
+655
+33% +$205K ﹤0.01% 794
2023
Q3 		$709K Buy
1,979
+221
+13% +$85.3K ﹤0.01% 758
2023
Q2 		$666K Buy
1,758
+250
+17% +$102K ﹤0.01% 735
2023
Q1 		$722K Sell
1,508
-290
-16% -$136K ﹤0.01% 775
2022
Q4 		$756K Sell
1,798
-6
-0.3% -$2.42K ﹤0.01% 855
2022
Q3 		$753K Sell
1,804
-2
-0.1% -$997 ﹤0.01% 863
2022
Q2 		$893K Sell
1,806
-20,198
-92% -$10.5M ﹤0.01% 874
2022
Q1 		$12.4M Sell
22,004
-3,436
-14% -$2.07M 0.02% 407
2021
Q4 		$19.2M Buy
25,440
+14,785
+139% +$11.1M 0.03% 392
2021
Q3 		$7.95M Buy
10,655
+7,312
+219% +$5.48M 0.01% 526
2021
Q2 		$2.15M Sell
3,343
-1,554
-32% -$946K ﹤0.01% 803
2021
Q1 		$2.8M Buy
4,897
+210
+4% +$124K 0.01% 717
2020
Q4 		$2.73M Buy
4,687
+800
+21% +$456K 0.01% 636
2020
Q3 		$2M Buy
+3,887
New +$1.97M 0.01% 641
2020
Q2 		– Sell
-55,668
Closed -$19.5M – 947
2020
Q1 		$19.5M Buy
55,668
+35,121
+171% +$12.9M 0.07% 219
2019
Q4 		$7.6M Sell
20,547
-8,599
-30% -$3.03M 0.02% 433
2019
Q3 		$9.7M Buy
+29,146
New +$9.51M 0.03% 374
2018
Q3 		– Sell
-6,900
Closed -$1.99M – 868
2018
Q2 		$1.99M Buy
+6,900
New +$1.91M 0.01% 506
2016
Q1 		– Sell
-75,000
Closed -$10.4M – 709
2015
Q4 		$10.4M Buy
+75,000
New +$10.4M 0.05% 177
2015
Q3 		– Sell
-150,000
Closed -$22.6M – 670
2015
Q2 		$22.6M Buy
+150,000
New +$21.5M 0.11% 104

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bank of Nova Scotia's BIO Position: Q2 2026 in Review

Bank of Nova Scotia opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 39,708 shares worth $11.7M. The stake represents 0.02% of the portfolio and ranks #453 among its holdings. This is a return to the name: Bank of Nova Scotia previously reported a position in BIO as recently as Q3 2024.

Bank of Nova Scotia first reported a position in BIO in Q2 2015 and has held it in 24 quarters since. The position peaked at $22.6M in Q2 2015. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Bank of Nova Scotia held 39,708 shares of Bio-Rad Laboratories Class A worth $11.7M as of Q2 2026.
  • Bio-Rad Laboratories Class A was a new Bank of Nova Scotia position in Q2 2026.
  • Bio-Rad Laboratories Class A made up 0.02% of Bank of Nova Scotia's portfolio in Q2 2026, its #453 holding.
  • Bank of Nova Scotia first reported a position in Bio-Rad Laboratories Class A in Q2 2015 and has held it in 24 quarters since.
  • Bank of Nova Scotia's Bio-Rad Laboratories Class A position peaked at $22.6M in Q2 2015.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Bank of Nova Scotia's 13F filing for Q2 2026, filed 12 Aug 2026.